Wouter Verhoeven

Wouter Verhoeven is a seasoned professional in the biotechnology and venture capital sectors, currently serving as Venture Partner at BGV and Chief Executive Officer at dualyx since September 2021. Previously, Wouter held the position of Chief Business Officer at NBE-Therapeutics, which developed pioneering antibody drug conjugates and was acquired by Boehringer Ingelheim in 2020. Wouter's extensive background includes leadership roles such as Head of Global Business and Corporate Development at mAbxience, Director of Business Development at myTomorrows, and Investment Manager at Rabo Private Equity. Earlier experience encompasses significant positions at Crucell and Berna Biotech AG, with a solid foundation in technical management from Delft University of Technology.